Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q-Linea Board/Management Information 2026

May 29, 2026

3100_rns_2026-05-29_2bf1ad43-e109-4925-842b-c13e1ec7a7ca.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Q-LINEA

Annika Blondeau Henriksson new interim CFO

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has hired Annika Blondeau Henriksson as CFO and IR. Annika takes office on June 15, 2026, when she succeeds Christer Samuelsson, who has held the position since 2023.

Annika Blondeau Henriksson has extensive experience in senior finance leadership roles across several industries, including as interim CFO at RaySearch Laboratories.

"I am very happy that Annika has chosen to accept the position as interim CFO and IR at Q-linea until a permanent CFO is hired. Christer's resignation has been planned since November 2025 when he expressed a desire to work closer to Stockholm and I wish Christer all the best in the future", says Stuart Gander, President and CEO Q-linea.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
[email protected]

Christer Samuelsson, CFO /IR, Q-linea AB
[email protected]
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.

Q-linea's flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.

Attachments

Annika Blondeau Henriksson new interim CFO

Q-linea • Dag Hammarskjölds väg 52A • SE-752 37 Uppsala